Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | YES1 | P07947 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15939103 | 0.99 | BRAF (0.63) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL20133847 | 0.87 | BRAF (0.69) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL24885869 | 0.86 | BRAF (0.48) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL15939192 | 0.84 | BRAF (0.60) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL4164155 | 0.84 | BRAF (0.65) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL4244844 | 0.83 | BRAF (0.61) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL5264312 | 0.81 | BRAF (0.59) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL4252815 | 0.80 | L3MBTL1 (0.59) | BRAFKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12499415 | 0.79 | BRAF (1.00) | BRAFRAF1YES1KDM4EALDH1A1 | |
| SCHEMBL4177014 | 0.78 | BRAF (0.58) | BRAFRAF1YES1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2024-05-02 | — | — | US | disclosed |
| WO-2023183470-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183470-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| EP-2739143-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | Flynn, Gary, A. (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013022766-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-2007736-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113557-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | BRAF 141/4885RAF1 93/4885YES1 483/4885 |
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | BRAF 49/4885RAF1 95/4885YES1 154/4885 |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | BRAF 49/4885RAF1 95/4885YES1 154/4885 |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885YES1 434/4885 |
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | BRAF, NRAS, RAF1 | BRAF 1/4885RAF1 3/4885YES1 319/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | BRAF 49/4885RAF1 95/4885YES1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.